Human IL-1α Monoclonal Antibodies With High-Affinity Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies lack specific and high-affinity human antibodies that effectively target interleukin 1 alpha (IL-1α) for therapeutic applications, particularly in modulating sterile inflammation and other IL-1α-related diseases.
Innovation Solution
Development of fully human monoclonal antibodies (mAbs) with high binding affinity for IL-1α, comprising specific light and heavy chain variable regions, encoded by sequences SEQ ID NO:1 and SEQ ID NO:2, which can be expressed in host cells and formulated for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing human antibodies are used, then they can bind to IL-1α, but they lack sufficient binding affinity for effective therapeutic intervention
Solution Approach 1:
The patent applies parameter changes by identifying and modifying specific amino acid residues in the antibody binding site. The invention focuses on residues in the heavy chain (positions 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100) and light chain (positions 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100) that directly contact IL-1α, and through targeted mutagenesis and affinity maturation, optimizes the binding parameters to achieve high affinity while maintaining human specificity
Solution Approach 2:
The patent employs copying by creating fully human monoclonal antibodies that replicate and optimize the natural human immune response. The invention uses human B-cell lines and phage display technology to generate and select antibody clones that precisely copy the binding characteristics needed for therapeutic efficacy, ensuring human specificity and avoiding immunogenicity issues associated with non-human antibodies
2Reliability
If non-human antibodies are used, then they can target IL-1α, but they may cause immunogenic reactions in human patients
Solution Approach 1:
The patent applies parameter changes by systematically altering the molecular parameters of the antibody to ensure human origin. The invention sequences and characterizes the heavy and light chains to confirm human immunoglobulin family membership, and through affinity maturation, optimizes the binding parameters while maintaining human sequence identity, thereby eliminating immunogenicity while preserving target specificity
Solution Approach 2:
The patent employs copying by generating fully human monoclonal antibodies that exactly replicate human immune system characteristics. The invention uses human B-cell lines and phage display technology to create antibodies that are molecular copies of natural human responses, ensuring compatibility with the human immune system and avoiding the immunogenic reactions caused by non-human antibodies
3Reliability
If high-affinity binding is achieved, then therapeutic efficacy is improved, but the complexity of antibody development increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody development process into distinct manageable stages: initial human B-cell line generation, phage display library construction, iterative panning and selection, sequence characterization, and affinity maturation. This segmentation allows systematic optimization of binding affinity while maintaining clear progress tracking and reducing overall development complexity through structured approach
Solution Approach 2:
The patent applies parameter changes by using phage display technology and systematic mutagenesis to iteratively optimize antibody binding parameters. The invention manipulates specific amino acid residues in the binding site through controlled parameter changes, achieving high affinity through measurable and controllable modifications rather than complex unpredictable processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed mAbs exhibit very high binding affinity for IL-1α, enabling effective therapeutic interventions with minimal adverse effects, and can be conjugated with cytotoxins or labels for targeted cell killing or detection.
Implementation Method 1
a monoclonal Ab (mAb) that binds human IL-1α with high affinity
Data Source
AI summary
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.